DNA damage and repair capacity in lymphocyte of chronic obstructive pulmonary diseases patients during physical exercise with oxygen supplementation

Table 3 Results of the Comet Assay in COPD patients

Comet assay	AE group				AE-O₂ group				p** between groups
Comet assay	Pre-exercise	Post-exercise	p*	∆	Pre-exercise	Post-exercise	p*	∆	p** between groups
Alkaline version	146.0 (92.5–209.5)	197.0 (94.5–974.0)	0.19	0 (−105.0–195.0)	248.0 (192.0–285.0)	302.0 (177.0–351.5)	0.20	11 (−137–169)	0.90
T0’ of MMS treatment	317.0 (277.0–366.5)	326.0 (239.0–370.5)	0.01	309.0 (193.0–392.0)	372.0 (30.5–394.5)	388.0 (339.0–398.0)	0.01	364.0 (168.0–392.0)	0.03
1 h of MMS treatment	317.0 (249.5–380.0)	296.0 (218.5–369.0)	0.18	−11.0 (−213.0–169.0)	336.0 (254.0–376.0)	368.0 (324.5–388.5)	0.01	17.0 (−40.0–283.0)	0.01
3 h of MMS treatment	259.0 (36.5–312.0)	240.0 (100.0–354.5)	0.19	4.0 (−52.0–114.0)	239.0 (154.0–295.0)	217.0 (163.0–271.0)	0.90	4.0 (−218.0–148.0)	0.37
Residual damage	62.9 (13.0–99.2)	81.6 (32.8–102.4)	0.51	1.7 (−97.1–36.3)	72.3 (48.2–94.0)	62.3 (49.8–85.5)	0.49	0.1 (−56.6–140.6)	0.33

Data are presented as Median (minimum-maximum);*Wilcoxon test; **Mann-Whitney U test; ∆: variation pre to post exercise; T0’: time zero of MMS treatment; h hours

ISSN: 2049-6958